Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Review the latest advances in treatment that target specific asthma phenotypes.
• Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
• Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, pulmonologists, and other health care professionals involved in the management of patients with asthma.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

• Review the latest advances in treatment that target specific asthma phenotypes.
• Outline the features of uncontrolled or persistent asthma and strategies for treatment intensification.
• Examine the latest evidence regarding new options for uncontrolled asthma and how these agents may fit into existing treatment algorithms.

Activity Description

An increasing body of evidence continues to define the presence of severe asthma subtypes that do not respond to conventional therapies. Guidelines from the European Respiratory Society as well as the American Thoracic Society recommend phenotypic assessment and consideration of select add-on biologic therapy for severe, poorly controlled asthma. Biologic therapies that modulate immunoglobulin E, interleukin (IL)-4/13, and IL-5 signaling pathways offer important options for patients whose asthma is inadequately controlled on standard therapy. Awareness of the latest evidence-based strategies for managing moderate to severe asthma will better enable health care professionals to tailor an individualized, targeted treatment approach. This Game On! activity is an interactive quiz in which participants answer questions, then select the level of confidence in their answers to achieve the highest score among their peers. Through this gaming activity, faculty will highlight advances in treatment that target specific asthma phenotypes; outline features of poorly controlled asthma and strategies for treatment intensification; and review the latest evidence regarding options for uncontrolled asthma.

Activity Chair

Michael E. Wechsler, MD, MMSc
Professor of Medicine
Director, Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, Cohero Health, Equillium, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, Sentien, Teva
Speakers Bureau: AstraZeneca, GlaxoSmithKline, Sanofi
Contracted Research: AstraZeneca, Sanofi

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Review the burden and complications resulting from influenza and how they may affect patients who are immunocompromised and/or immunosuppressed.
• Utilize evidence-based algorithms when interpreting the results of diagnostic tests for influenza.
• Incorporate the most appropriate influenza treatment regimen in patients at high risk for complications, based on evidence of the regimen’s safety and efficacy in these patients.

Activity Description

Influenza places a substantial burden on the health of both children and adults in the United States each year. While immunization helps to prevent flu infection, there is a need for improved treatments, preventative measures, and better mitigation for the impact associated with a pandemic, especially in high-risk patients who have comorbid illnesses or who are immunocompromised. In particular, patients with rheumatic disorders are highly vulnerable to infections because of abnormalities in their immune system, and the immunosuppressive effects of their medications. They are a high-risk group for influenza virus infection as well as for complications from the virus. Therefore, it is important that rheumatology providers are competent in their management of patients who have a rheumatic disease and are either exposed to or contract influenza. In this GameOn! educational activity, knowledge will be tested on the latest updates in the diagnosis and management of influenza.

Faculty

Cassandra Calabrese, DO
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie
Speakers Bureau: Regeneron

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Vindico Medical Education staff have no relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Review the burden and complications resulting from influenza and how they may affect patients who are immunocompromised and/or immunosuppressed.
• Utilize evidence-based algorithms when interpreting the results of diagnostic tests for influenza.
• Incorporate the most appropriate influenza treatment regimen in patients at high risk for complications, based on evidence of the regimen’s safety and efficacy in these patients.

Activity Description

Influenza places a substantial burden on the health of both children and adults in the United States each year. While immunization helps to prevent flu infection, there is a need for improved treatments, preventative measures, and better mitigation for the impact associated with a pandemic, especially in high-risk patients who have comorbid illnesses or who are immunocompromised. In particular, patients with rheumatic disorders are highly vulnerable to infections because of abnormalities in their immune system, and the immunosuppressive effects of their medications. They are a high-risk group for influenza virus infection as well as for complications from the virus. Therefore, it is important that rheumatology providers are competent in their management of patients who have a rheumatic disease and are either exposed to or contract influenza. In this GameOn! educational activity, knowledge will be tested on the latest updates in the diagnosis and management of influenza.

Faculty

Cassandra Calabrese, DO
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie
Speakers Bureau: Regeneron

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Vindico Medical Education staff have no relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

• Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
• Summarize the latest evidence related to complications associated with gout
• Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

• Systemic burden of gout
• Gout comorbidities
• Allopurinol
• Febuxostat
• Pegloticase

Statement of Educational Need

• Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
• Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
• Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
2. Faculty reviews study methodology [1 min]
   1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
3. Faculty summarizes key findings [3-4 min]
   1. How the data advances the current treatment landscape/paradigms
   2. How the data should be positioned among ongoing research
   3. How the data connects with current research imperatives
   4. Clinical significance/implications for current knowledge or practice
   5. Data one might be expected from the trial in the future
4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio

Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Accredited By

Target Audience

Rheumatologists, nephrologists, and other healthcare professionals involved in the care of patients with gout.

Learning Objectives

• Summarize the latest evidence related to combination pharmacologic treatment of patients with gout who do not achieve the target serum urate level with monotherapy
• Summarize the latest evidence related to complications associated with gout
• Incorporate evidence-based research into clinical practice

Activity Description

OVERVIEW
Dr. Brian Mandell and Dr. Naomi Schlesinger discuss recent published evidence related to gout, as well as study results presented at the American College of Rheumatology Convergence 2020 virtual annual meeting. Dr. Schlesinger begins with an introduction to this CME activity by touching on a recent published systematic review indicating that the manifestations of gout extend beyond the joints, affecting other organs and tissues. Dr. Schlesinger also provides an overview of some of the challenges encountered in clinical practice with the use of urate-lowering therapy. In module 1, Dr. Schlesinger focuses on 2 abstracts presented at ACR Convergence 2020 concerning gout-related comorbidities, particularly cardiovascular disease. In module 2, Dr. Mandell focuses on 2 abstracts related to the safety and use of urate-lowering therapy, specifically allopurinol, febuxostat, and pegloticase. In module 3, Dr. Mandell discusses 2 abstracts related to the systemic nature of gout; 1 abstract focuses on heart failure, while the other focuses on the lumbar spine.

CONTENT AREAS

• Systemic burden of gout
• Gout comorbidities
• Allopurinol
• Febuxostat
• Pegloticase

Statement of Educational Need

• Increased understanding of the safety and efficacy of combination treatment with medications with different mechanisms for lowering the serum urate level
• Increased understanding of updated recommendations regarding the use of combination urate-lowering therapy
• Increased understanding of the association of gout with systemic complications involving the heart, kidneys, and other organs

Agenda

Modules will be structured and recorded in a manner that best supports the nature of the data published by each study. In general, this structure will be:

1. Faculty welcomes the learner, introduces the study, states why the study was included in this program [1 min]
2. Faculty reviews study methodology [1 min]
   1. For emphasis or clarity, charts, graphs, or PowerPoint slides may be edited into the final video
3. Faculty summarizes key findings [3-4 min]
   1. How the data advances the current treatment landscape/paradigms
   2. How the data should be positioned among ongoing research
   3. How the data connects with current research imperatives
   4. Clinical significance/implications for current knowledge or practice
   5. Data one might be expected from the trial in the future
4. Faculty provides commentary [5-8 min]

Note: this structure may vary slightly when two smaller studies or abstracts are presented in the same module.

Faculty

Brian Mandell, MD, PhD
Professor of Medicine
Chairman of Academic Medicine
Cleveland Clinic
Cleveland, Ohio

Naomi Schlesinger, MD
Professor of Medicine
Chief, Division of Rheumatology
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty
Brian Mandell, MD, PhD
Consultant: Horizon
Data Monitoring Safety Board: Horizon
Speakers Bureau: Genentech

Naomi Schlesinger, MD
Advisory Board: IFM, Johnson and Johnson
Research Support: Amgen, Pfizer
Speakers Bureau: Horizon

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Statement of Commercial Support

This activity is supported by an educational grant from Horizon Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be no discussion about the use of products for non-FDA approved applications.

Additional content planners
The following have no significant relationship to disclose:
Greg Scott, PharmD (Medical writer)
Eugene Cullen, MD (Peer Reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information for Questions About the Activity

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.

Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis

Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.

Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.

Activity Details

Accredited By

Target Audience

This activity is intended for neurologists, psychiatrists, and other clinicians involved in the care of patients with AD.

Learning Objectives

1. Assess patient factors that may affect eligibility for treatment with amyloid-targeted disease modifying therapies (DMTs) to determine for which patients this strategy holds the most promise if approved.
2. Evaluate expert opinions of and available Phase 2/3 data with amyloid-targeting DMTs to assess their potential role in future patient management.

Activity Description

In November of 2020, 26 renowned AD specialists completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field. In this activity, three of these experts discuss opinions of those surveyed as well as their own on each of these highly contested topics such as the most prominent drivers of AD and the potential role of amyloid-targeting agents. Using video- and text-based elements, this intervention is designed to not only keep knowledge up to date but also prepare learners for a potential paradigm shift in the way AD is managed in the clinic. Part 2 will focus on the treatments currently available for AD contrasted with the rising agents that have the potential to enter the treatment armamentarium in the near future.

Statement of Educational Need

AD is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking. Should the field continue to evolve in the projected manner, these practitioners will need to be prepared for the multitude of considerations that will become relevant to contemporary practice.

Agenda

In the second of this three-part series, Drs. Sabbagh, Smith, and Isaacson will discuss the use and limitations of currently available AD therapies as well as the potential role of rising, disease-specific therapies that are on the horizon.

Faculty

Marwan Sabbagh, MD (Chair)
Director, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

DR. SABBAGH reported the following financial relationships:
ROYALTY: Harper Collins
CONSULTING FEES: Acadia Pharmaceuticals Inc., Alzheon, Biogen Inc., Cortexyme Inc., Danone, Genentech/Roche, Neurotrope Inc., Stage 2 Innovations
CONTRACTED RESEARCH: Keep Memory Alive Foundation, National Institutes of Health
FEES FOR NON-CME/CE SERVICES: Health and Wellness Partners, Joyce Knapp Communications
OWNERSHIP INTEREST (<5%): Athira, Brain Health Inc., Optimal Cognitive Health Co., NeuroTau Inc., NeuroReserve Inc., uMethod Health Inc., Versanum Inc.

Amanda Smith, MD
Director, Clinical Research at Byrd Alzheimer’s Institute
University of South Florida
Tampa, Florida

DR. SMITH reported the following financial relationships:
CONTRACTED RESEARCH: AbbVie Inc., Biogen Inc., Biohaven Pharmaceuticals Inc., Eisai, Janssen Pharmaceuticals Inc., Lilly, NeuroEM Therapeutics Inc., Novartis

Richard Isaacson, MD
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York

DR. ISAACSON reported no financial relationships.

Conflict of Interest Policy/Disclosure Statement

Conflict of Interest Disclosure Policy
PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure
PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Designation of Credit

PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive CME credits, participants must complete the pre- and post-assessment questions, and program evaluation. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine (www.pimed.com) at 1-800-423-3576 or email to inquiries@pimed.com.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For any questions about this activity, feel free to email us at contact@efficientcme.com.